21-hydroxylase deficiency differential diagnosis: Difference between revisions
Line 9: | Line 9: | ||
==Differentiating congenital adrenal hyperplasia due to 21-hydroxylase deficiency from other diseases== | ==Differentiating congenital adrenal hyperplasia due to 21-hydroxylase deficiency from other diseases== | ||
[[Congenital adrenal hyperplasia]] due to 21-hydroxylase deficiency classic type must be differentiated from diseases that cause [[ambiguous genitalia]]:<ref name="pmid17875484">{{cite journal |vauthors=Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT |title=Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development |journal=Best Pract. Res. Clin. Endocrinol. Metab. |volume=21 |issue=3 |pages=351–65 |year=2007 |pmid=17875484 |doi=10.1016/j.beem.2007.06.003 |url=}}</ref><ref name="pmid10857554">{{cite journal |vauthors=White PC, Speiser PW |title=Congenital adrenal hyperplasia due to 21-hydroxylase deficiency |journal=Endocr. Rev. |volume=21 |issue=3 |pages=245–91 |year=2000 |pmid=10857554 |doi=10.1210/edrv.21.3.0398 |url=}}</ref> | [[Congenital adrenal hyperplasia]] due to 21-hydroxylase deficiency classic type must be differentiated from diseases that cause [[ambiguous genitalia]]:<ref name="pmid17875484">{{cite journal |vauthors=Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT |title=Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development |journal=Best Pract. Res. Clin. Endocrinol. Metab. |volume=21 |issue=3 |pages=351–65 |year=2007 |pmid=17875484 |doi=10.1016/j.beem.2007.06.003 |url=}}</ref><ref name="pmid10857554">{{cite journal |vauthors=White PC, Speiser PW |title=Congenital adrenal hyperplasia due to 21-hydroxylase deficiency |journal=Endocr. Rev. |volume=21 |issue=3 |pages=245–91 |year=2000 |pmid=10857554 |doi=10.1210/edrv.21.3.0398 |url=}}</ref> | ||
{| class="wikitable" | {| class="wikitable"class="wikitable" align="center" style="border: 0px; font-size: 90%; margin: 3px;" | ||
!Disease name | ! colspan="2" rowspan="3" align="center" style="background: #4479BA; color: #FFFFFF; " |Disease name | ||
! colspan="2" |Laboratory tests | ! colspan="2" |Laboratory tests | ||
!Important clinical findings | !Important clinical findings | ||
Line 81: | Line 81: | ||
|Gestational [[hyperandrogenism]] | |Gestational [[hyperandrogenism]] | ||
| | | | ||
* Maternal serum [[androgen]] concentrations (usually [[testosterone]] and [[androstenedione]]) are high | * Maternal serum [[androgen]] concentrations (usually [[testosterone]] and [[androstenedione]]) are high | ||
* If [[virilization]] is caused by exogenous hormone administration, the values may be low because the offending hormone is usually a synthetic [[steroid]] not measured in assays for [[testosterone]] or other [[androgens]] | * If [[virilization]] is caused by exogenous hormone administration, the values may be low because the offending hormone is usually a synthetic [[steroid]] not measured in assays for [[testosterone]] or other [[androgens]] | ||
| | | | ||
Line 94: | Line 95: | ||
{| class="wikitable" | {| class="wikitable" | ||
!Disease name | ! rowspan="2" |Disease name | ||
! | ! colspan="2" |[[Adrenal]] hormones status | ||
!Other laboratory | ! rowspan="2" |Other laboratory | ||
!Important clinical findings | ! rowspan="2" |Important clinical findings | ||
|- | |||
!Increased | |||
!Decreased | |||
|- | |- | ||
|Non-classic type of 21-hydroxylase deficiency | |Non-classic type of 21-hydroxylase deficiency | ||
| | | | ||
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | * [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | ||
* Exaggerated [[Androstenedione]], [[DHEA]], and [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | * Exaggerated [[Androstenedione]], [[DHEA]], and [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | ||
response to | response to ACTH | ||
| | |||
| | | | ||
* Low [[testosterone]] levels | * Low [[testosterone]] levels | ||
Line 112: | Line 117: | ||
|- | |- | ||
|[[11β-hydroxylase deficiency|11-β hydroxylase deficiency]] | |[[11β-hydroxylase deficiency|11-β hydroxylase deficiency]] | ||
| | | | ||
* | * [[Deoxycorticosterone]] | ||
* 11-Deoxy-[[ | * 11-Deoxy-[[cortisol]] | ||
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]], mild elevation | |||
| | |||
* [[Cortisol]] | * [[Cortisol]] | ||
* [[Corticosterone]] | * [[Corticosterone]] | ||
* [[Aldosterone]] | * [[Aldosterone]] | ||
| | | | ||
* Low [[testosterone]] levels | * Low [[testosterone]] levels | ||
Line 126: | Line 132: | ||
|- | |- | ||
|3β-Hydroxysteroid Dehydrogenase | |3β-Hydroxysteroid Dehydrogenase | ||
| | | | ||
* [[DHEA]] | * [[DHEA]] | ||
* [[17-hydroxypregnenolone]] | * [[17-hydroxypregnenolone]] | ||
* [[Pregnenolone]] | * [[Pregnenolone]] | ||
| | |||
* [[Cortisol]] | * [[Cortisol]] | ||
* [[Aldosterone]] | * [[Aldosterone]] | ||
Line 143: | Line 149: | ||
| | | | ||
* High [[DHEAS]] and [[androstenedione]] levels | * High [[DHEAS]] and [[androstenedione]] levels | ||
| | |||
| | | | ||
* Low [[testosterone]] levels | * Low [[testosterone]] levels | ||
Line 154: | Line 161: | ||
| | | | ||
* Variable levels depends on [[tumor]] type | * Variable levels depends on [[tumor]] type | ||
| | |||
| | | | ||
* Low [[testosterone]] level | * Low [[testosterone]] level | ||
Line 163: | Line 171: | ||
| | | | ||
* Variable levels depends on [[tumor]] type | * Variable levels depends on [[tumor]] type | ||
| | |||
| | | | ||
* [[Testosterone]] is high | * [[Testosterone]] is high | ||
Line 173: | Line 182: | ||
* Increase [[cortisol]] & metabolites | * Increase [[cortisol]] & metabolites | ||
* Variable other [[steroids]] | * Variable other [[steroids]] | ||
| | |||
| | | | ||
* Variable [[mineralocorticoid]] excess | * Variable [[mineralocorticoid]] excess | ||
Line 181: | Line 191: | ||
| | | | ||
* Normal levels of most of [[steroids]] | * Normal levels of most of [[steroids]] | ||
| | |||
| | | | ||
* Increased [[prolactin]] | * Increased [[prolactin]] |
Revision as of 14:24, 1 August 2017
21-hydroxylase deficiency Microchapters |
Differentiating 21-Hydroxylase Deficiency from other Diseases |
Diagnosis |
Treatment |
Case Studies |
21-hydroxylase deficiency differential diagnosis On the Web |
American Roentgen Ray Society Images of 21-hydroxylase deficiency differential diagnosis |
21-hydroxylase deficiency differential diagnosis in the news |
Risk calculators and risk factors for 21-hydroxylase deficiency differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Mehrian Jafarizade, M.D [2]
Overview
21-hydroxylase deficiency must be differentiated from 11-β hydroxylase deficiency, 17-α hydroxylase deficiency, androgen insensitivity syndrome, 3β-Hydroxysteroid Dehydrogenase, polycystic ovarian syndrome, hyperprolactinemia, cushing syndrome, and adrenal tumor.
Differentiating congenital adrenal hyperplasia due to 21-hydroxylase deficiency from other diseases
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency classic type must be differentiated from diseases that cause ambiguous genitalia:[1][2]
Disease name | Laboratory tests | Important clinical findings | ||
---|---|---|---|---|
Increased | Decreased | |||
Classic type of 21-hydroxylase deficiency |
|
| ||
11-β hydroxylase deficiency |
|
| ||
17-α hydroxylase deficiency |
| |||
3β-Hydroxysteroid Dehydrogenase |
| |||
Gestational hyperandrogenism |
|
|
21-hydroxylase deficiency Non-classic type must be differentiated from diseases that cause virilization and hirsutism in female:[3][2][4]
Disease name | Adrenal hormones status | Other laboratory | Important clinical findings | |
---|---|---|---|---|
Increased | Decreased | |||
Non-classic type of 21-hydroxylase deficiency |
response to ACTH |
|
| |
11-β hydroxylase deficiency |
|
|
||
3β-Hydroxysteroid Dehydrogenase |
|
| ||
Polycystic ovary syndrome |
|
|
||
Adrenal tumors |
|
|
| |
Ovarian virilizing tumor |
|
|
| |
Cushing's syndrome |
|
| ||
Hyperprolactinemia |
|
|
References
- ↑ Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT (2007). "Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development". Best Pract. Res. Clin. Endocrinol. Metab. 21 (3): 351–65. doi:10.1016/j.beem.2007.06.003. PMID 17875484.
- ↑ 2.0 2.1 White PC, Speiser PW (2000). "Congenital adrenal hyperplasia due to 21-hydroxylase deficiency". Endocr. Rev. 21 (3): 245–91. doi:10.1210/edrv.21.3.0398. PMID 10857554.
- ↑ Hohl A, Ronsoni MF, Oliveira M (2014). "Hirsutism: diagnosis and treatment". Arq Bras Endocrinol Metabol. 58 (2): 97–107. PMID 24830586. Vancouver style error: initials (help)
- ↑ Melmed, Shlomo (2016). Williams textbook of endocrinology. Philadelphia, PA: Elsevier. ISBN 978-0323297387.=